Literature DB >> 19073435

Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival.

Michelle A Gauthier1, Joseph K Eibl, James A G Crispo, Gregory M Ross.   

Abstract

Metallothioneins are a group of low molecular weight proteins which can be induced upon exposure to metal ions, including Zn(II). These cysteine-rich proteins are believed to have antioxidant-like properties due to their ability to scavenge free radicals with their multiple sulfhydryl groups. Dopamine is a neurotransmitter that can form toxic quinone and semi-quinone products in an oxidative environment. While Zn(II) is known to be toxic to some neuron subtypes, here we report a beneficial effect of Zn(II) on dopaminergic neurons and identify a mechanism through which metallothionein may scavenge toxic dopamine oxidation products. Cultured embryonic neurons were treated with Zn(II), and the number of dopaminergic neurons surviving after two or three weeks in culture was determined. We demonstrate that under these conditions metallothionein is upregulated and is able to form covalent arylation products with dopamine and 6-hydroxydopamine both in vitro and in culture. These experiments suggest that Zn(II) enhances the survival of dopaminergic neurons, and we propose that as a mechanism, upregulated metallothioneins form covalent adducts with both dopamine and 6-hydroxydopamine, resulting in the observed neuroprotective effect of Zn(II) on these cells. As Zn(II) homeostasis and modulation of metallothionein expression are hallmarks of neurodegeneration, these studies may have significant implications for understanding the underlying basis of degenerative diseases involving dopaminergic neurons, including Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073435     DOI: 10.1007/BF03033856

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  39 in total

Review 1.  Synaptic and mitochondrial physiopathologic changes in the aging nervous system and the role of zinc ion homeostasis.

Authors:  Carlo Bertoni-Freddari; Eugenio Mocchegiani; Marco Malavolta; Tiziana Casoli; Giuseppina Di Stefano; Patrizia Fattoretti
Journal:  Mech Ageing Dev       Date:  2006-03-07       Impact factor: 5.432

2.  Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease.

Authors:  Estefanía Méndez-Alvarez; Ramón Soto-Otero; Alvaro Hermida-Ameijeiras; Ana María López-Real; José Luis Labandeira-García
Journal:  Biochim Biophys Acta       Date:  2002-03-16

3.  Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.

Authors:  Jin Xu; Shyan-Yuan Kao; Frank J S Lee; Weihong Song; Lee-Way Jin; Bruce A Yankner
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

4.  Regulation of metallothionein gene expression by oxidative stress and metal ions.

Authors:  G K Andrews
Journal:  Biochem Pharmacol       Date:  2000-01-01       Impact factor: 5.858

5.  Identification of novel catecholamine absorbing proteins in the central nervous system.

Authors:  G M Ross; B E McCarry; S Thakur; R K Mishra
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

6.  Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family.

Authors:  Malene Ambjørn; Johanne W Asmussen; Mats Lindstam; Kamil Gotfryd; Christian Jacobsen; Vladislav V Kiselyov; Søren K Moestrup; Milena Penkowa; Elisabeth Bock; Vladimir Berezin
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

7.  Zinc induces motor neuron death via a selective inhibition of brain-derived neurotrophic factor activity.

Authors:  Joan Isabel Post; Joseph Karl Eibl; Gregory Michiel Ross
Journal:  Amyotroph Lateral Scler       Date:  2008-06

8.  Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain.

Authors:  Masato Asanuma; Ikuko Miyazaki; Youichirou Higashi; Ken-ichi Tanaka; Md Emdadul Haque; Naoko Fujita; Norio Ogawa
Journal:  Neurosci Lett       Date:  2002-07-12       Impact factor: 3.046

9.  Effect of zinc, copper and glucocorticoids on metallothionein levels of cultured neurons and astrocytes from rat brain.

Authors:  J Hidalgo; A García; A M Oliva; M Giralt; T Gasull; B González; H Milnerowicz; A Wood; I Bremner
Journal:  Chem Biol Interact       Date:  1994-12       Impact factor: 5.192

Review 10.  Metallothionein (MT) isoforms in the central nervous system (CNS): regional and cell-specific distribution and potential functions as an antioxidant.

Authors:  M Aschner
Journal:  Neurotoxicology       Date:  1998 Aug-Oct       Impact factor: 4.294

View more
  5 in total

1.  Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line.

Authors:  Irmgard Paris; Carolina Perez-Pastene; Sergio Cardenas; Patricio Iturriaga-Vasquez; Patricio Iturra; Patricia Muñoz; Eduardo Couve; Pablo Caviedes; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2010-01-20       Impact factor: 3.911

Review 2.  Redox biochemistry of mammalian metallothioneins.

Authors:  Wolfgang Maret
Journal:  J Biol Inorg Chem       Date:  2011-06-07       Impact factor: 3.358

Review 3.  Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease.

Authors:  Aracely Garcia-Garcia; Laura Zavala-Flores; Humberto Rodriguez-Rocha; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2012-05-03       Impact factor: 8.401

4.  Molecular and neurochemical mechanisms in PD pathogenesis.

Authors:  Irmgard Paris; Jorge Lozano; Carolina Perez-Pastene; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2009-05-20       Impact factor: 3.911

Review 5.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.